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1  | INTRODUC TION
Invasive	 pulmonary	 aspergillosis	 (IPA)	 remains	 a	 major	 cause	 of	
morbidity	 and	mortality	 among	 severely	 ill	 patients.	 The	 critical	
step	 for	 successful	management	 of	 IPA	 is	 rapid	 initiation	 of	 an-
tifungal	 therapy	 requiring	 early	 and	 reliable	diagnosis.1,2 Several 
diagnostic	 approaches	 including	 antigen	 testing,	 new	 imaging	
methods	 and	 molecular	 approaches	 have	 been	 investigated	 to	




for	 detection	 of	 fungal	 infections	when	 testing	 bronchoalveolar	
lavage	 fluid	 (BALF)	 from	 immunocompromised	 patients.6-11	 The	
newly	developed	AspID	(OLM	Diagnostics,	Newcastle,	UK)	assay	
is	a	multiplex	real-	time	PCR	assay	designed	to	detect	clinically	rel-






In	 this	 study,	 the	 performance	 of	 the	 new	 AspID	 PCR	 assay	
was	 investigated	 for	 the	 first	 time	using	both	 the	Quality	Control	
for	Molecular	Diagnostics	(QCMD)	2016	Aspergillus	spp.	DNA	EQA	
Programme	panel	and	human	BALF	samples.
2  | MATERIAL AND METHODS
The	 accuracy	 of	 the	AspID	was	 determined	 utilising	 the	QCMD	
2016 Aspergillus	 spp.	 DNA	 EQA	 Programme	 panel.	 The	 panel	
consisted	 of	 9	 members	 including	 Aspergillus fumigatus	 DNA	
(n	=	3),	Aspergillus fumigatus	conidia	 (n	=	3),	and	negatives	 (n	=	3).	
Members	 were	 either	 spiked	 in	 TE	 puffer,	 synthetic	 sputum,	 or	
in	plasma	matrix.	In	addition,	36	BALF	samples	obtained	from	18	
patients	with	IPA	and	18	patients	without	IPA	were	investigated.	
Samples	were	obtained	between	2013	 and	2016	 at	 the	Medical	
University	of	Graz,	Austria.	BALF	samples	were	 stored	at	−70°C	
immediately	after	collection	and	have—in	part—been	used	in	stud-
ies	 published	 recently.4,6,13-15	 Patients	 were	 classified	 as	 having	
IPA	if	BALF	galactomannan	(GM)	levels	showed	an	optical	density	
index	 of	 >3.0	 and	 patients	 had	 clinical	 and	 radiological	 findings	
compatible	with	 presence	 of	 IPA,	 as	 suggested	 by	D’Haese	 and	
colleagues.16	 Patients	 without	 IPA	 had	 BALF-	GM	 levels	 of	 <0.5	
and	no	clinical	or	radiological	findings	suggestive	for	presence	of	
IPA.	Patients	were	matched	1:1	according	 to	 IPA	status,	primary	
underlying	 disease,	 and	 intensive	 care	 unit	 admission.	 For	 this	
study,	diagnosis	of	IPA	was	based	on	high	BALF-	GM	levels,	clinical	
and	 radiological	 findings.	We	did	not	utilise	 the	 revised	EORTC/
MSG	criteria,	as	these	criteria	are	designed	for	diagnosis	of	inva-




BALF	 samples	 were	 thawed	 and	 immediately	 tested	 for	 pres-
ence	of	Aspergillus	DNA	 in	an	 International	Standard	Organization	
(ISO	 9001:2008)-	certified	 laboratory,	 the	 Molecular	 Diagnostics	
Laboratory,	 IHME,	 Medical	 University	 of	 Graz.	 Investigators	 per-




(bioMerieux)	 using	 the	 specific	 B	 protocol.	 The	 input	 volume	was	












Inc.,	 Chicago,	 IL,	 USA).	 Receiver	 operating	 characteristic	 (ROC)	
curves	analyses	were	performed	utilising	number	of	AspID	cycles	in	
case	of	 positivity	 and	 area	under	 the	 curve	 (AUC)	 values	 are	pre-
sented	 including	 95%	 CI.	 Optimal	 cut-	offs	 were	 calculated	 using	












characteristics	 of	 patients	 with	 and	 without	 IPA	 are	 displayed	 in	
Table	2.	When	36	BALF	samples	were	investigated	with	the	AspID 
assay,	 2	 samples,	 including	 one	 from	 a	 patient	 with	 IPA	 and	 one	
from	 a	 patient	without	 IPA,	 showed	 inhibition	 and	were	 excluded	
from	analysis.	Twenty	BALF	samples	were	found	to	be	positive	for	
Aspergillus	 and	negative	 for	Aspergillus terreus	 and	14	negative	 for	
both	targets.	When	AspID	results	were	compared	to	those	obtained	
from	BALF	GM	determination,	29	(85.3%)	were	found	to	be	concor-
dant	 and	5	 (14.7%)	discordant.	Overall,	 16/17	BALF	 samples	 from	
patients	with	IPA	turned	out	as	true	positive	and	one	as	false	neg-
ative.	Thirteen	out	of	17	BALF	samples	 from	patients	without	 IPA	






with	 IPA	 (true	positive)	 showed	a	median	crossing	point	 (cp)	value	
of	25.5,	whereas	positive	AspID	 results	 from	patients	without	 IPA	
















ated	with	 the	 2016	Aspergillus	QCMD	proficiency	 panel	 and	with	
BALF	samples	from	patients	at	risk	for	IPA	for	the	first	time.
With	both	the	QCMD	programme	panel	and	the	BALF	samples	






























































IPA.	For	 routine	clinical	use,	sensitivity	has	 to	be	 investigated	 in	a	
larger	cohort	of	patients	presenting	intermediate	BALF-	GM	levels.
Clinical	specificity	was	slightly	above	76%	with	4	out	of	17	pa-
tients	 without	 IPA	 having	 a	 positive	AspID	 result.	 However,	 false	
positive	samples	showed	significantly	higher	cp	values	indicating	low	











patients	 usually	 receive	mold	 active	 antifungal	 prophylaxis	 poten-






all	 clinical	 samples	 contained	 only	 Aspergillus fumigatus or were 
culture	negative.	None	of	the	samples	tested	contained	Aspergillus 
terreus.	 The	 clinical	 performance	 of	AspID	 regarding	 detection	 of	
Aspergillus terreus	can	thus	not	be	calculated	from	this	study.
Molecular	diagnostic	approaches	for	detection	of	IPA	have	been	
constantly	 improved	 within	 the	 last	 years	 and	 yielded	 promising	
results	 in	clinical	studies,21,22	especially	when	combined	with	anti-
gen	testing.6,13,18	 In	addition,	performance	of	PCR	testing	of	BALF	






performance	 in	 blood	 significantly,	 influence	 on	 performance	 of	
BALF	PCR	testing	is	of	less	extent.19,23	One	of	the	major	drawbacks	
for	PCR	assays	used	for	detection	of	Aspergillus	DNA	testing	is	stan-
dardisation.	 Today,	 the	majority	 of	 those	 assays	 are	 still	 based	on	




of	 PCR	 assays,	 performance	 of	 bronchoscopy	 and	 BALF	 sampling	
may	also	influence	assay	performance,	for	example	due	to	different	
volumes,	concentrations,	contamination	or	use	of	mucolytic	agents.	
The	 latter	 have	 shown	 to	 significantly	 alter	 the	 performance	 of	
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